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H 
uman T  cell lymphotropic virus type I (HTLV-I) is a 
mammalian  retrovirus that  has a tropism  for mature 
T lymphocytes and an association with rare clinical disorders 
(1, 2). HTLV-I infection is endemic in a number of geographic 
regions which include parts of Japan, the Caribbean, South 
America, and Africa. Despite very high rates of infection in 
endemic areas where as many as 30% of the population may 
be infected, relatively few infected individuals develop disease, 
and it has been estimated that the lifetime risk of developing 
a HTLV-I-related clinical  disorder is less than 5% (1, 3, 4). 
The vast majority of infected individuals remain as asymp- 
tomatic carriers,  and serve as a source of further transmission 
of the  virus.  Transmission  occurs  by three  major  routes: 
vertically  from  mother  to  child,  which  occurs  primarily 
through breast-feeding; heterosexual and homosexual trans- 
mission; and via contaminated blood products, which may 
occur after blood transfusion or by intravenous drug abuse 
(1,  2).  Outside  of established  endemic  areas, the  rates  of 
infection are unknown, but appear to be comparatively low. 
In the United States, studies on randomly chosen blood donors 
have indicated that  this may be in the region  of 0.0016% 
(2), and similar rates probably exist in Europe. In nonendemic 
areas,  the modes of transmission  are presumably the  same 
as in endemic regions.  However, it seems likely that blood 
transfusion  is very important  in those countries where the 
blood supply is not routinely screened for HTLV-I infection. 
In endemic areas,  HTLV-I infection is associated with  a 
number of diverse clinical disorders. These include adult T 
cell leukemia (ATL), a malignancy of CD4 + lymphocytes, 
and a form of cutaneous T cell leukemia/lymphoma (CTCL) 
(5, 6), a chronic encephalomyelopathy known both as tropical 
spastic  paraparesis  and  HTLV-I-associated  myelopathy 
(TSP/HAM)  (7,  8),  and  a characteristic  uveitis,  HTLV-I- 
associated uveitis  (HUV)  (9,  10).  In  addition,  there  have 
been suggestions that HTLV-I may be associated with other 
inflammatory processes including T cell alveolitis (11), poly- 
myositis (12), arthritis (13, 14), infective dermatitis (15), and 
Sjogrens syndrome (16). However, it is unclear if the association 
of infection with the latter group of disorders is merely co- 
incidental,  and further studies will be required to definitely 
establish a role of the virus in their pathogenesis.  Very recently, 
there have been suggestions that in certain nonendemic areas, 
HTLV-I may be associated with a number of CTCLs other 
than ATL. This view is strongly supported in a publication 
by Manca et al. (17) in this issue of The Journal of  Experimental 
Medicine where the PCR was employed to detect HTLV-I 
infection in patients with mycosis fungoides.  In this com- 
mentary,  the evidence for a role of HTLV-I in the etiology 
of CTCLs will be reviewed and  summarized. 
ATL, which was first recognized as a unique dinical dis- 
order in Japan in the 1970s (18),  is a malignancy of mature 
CD4 § T lymphocytes with characteristic  cutaneous involve- 
ment.  The disorder has been classified  into four types:  the 
so-called  acute, chronic,  smouldering,  and lymphoma types 
(10). The acute form of the disease is an extremely aggressive 
disorder characterized by a high-grade leukemia, skin lesions, 
and widespread systemic involvement resulting from infiltra- 
tion of leukemic cells in liver,  spleen, lungs,  lymph nodes, 
and bone marrow.  In addition,  lytic bone lesions with  an 
associated hypercalcemia commonly occurs.  Cutaneous in- 
volvement is characterized by infiltration  of leukemic cells 
primarily into the dermis and subcutaneous tissues.  While 
epidermal infiltration also occurs, this is comparatively rare. 
The HTLV-I provirus is monoclonally integrated in the leu- 
kemic cells, and the majority of patients have high levels of 
antibody to HTLV-I. Leukemic cells characteristically display 
activation markers including CD25 (IL-2R) and HLA-DR 
(1, 10). Chronic ATL is a much less aggressive form of the 
disease. Patients generally have skin involvement, but systemic 
involvement as occurs in acute ATL is rare. While many pa- 
tients.display a lymphocytosis, only small numbers of abnormal 
cells are present in peripheral blood (10). Smouldering ATL 
is an even more indolent process. Characteristically,  this is 
of long duration and presents as cutaneous disease with few, 
if any,  of the other features of acute ATL. Lymphocytosis 
is generally not evident and there are few or no abnormal 
lymphocytes in peripheral blood. Both chronic and smoul- 
dering ATL are considered to be pre-leukemic states with overt 
acute disease developing after many years of latency (10, 19). 
Lymphoma type ATL is characterized by prominent lymph- 
adenopathy due to the presence of HTLV-I-transformed T 
lymphocytes in lymphatic tissues, but the leukemic compo- 
nent  observed in acute ATL is absent. 
The observation that chronic and smouldering ATL may 
be pre-leukemic conditions has led to the hypothesis that the 
development of acute ATL is a progressive process beginning 
with  the infected  asymptomatic  carrier  through  an  inter- 
mediate state of the chronic/smouldering  forms of the dis- 
ease and eventually to overt ATL (10, 19). During these stages 
the integration  pattern  of the provirus changes from poly- 
clonal in the carrier and intermediate states to monoclonal, 
which is characteristic of the transformed leukemic cells. The 
mechanisms involved in cellular transformation remain poorly 
understood. HTLV-I does not contain an oncogene as exists 
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transformation  (20). Similarly,  there is no evidence that in- 
fection results in the activation of cellular oncogenes. Studies 
have demonstrated that  in patients  with ATL there are no 
common sites of virus integration in host chromosomal DNA, 
suggesting that c/s-activation of a proto-oncogene adjacent 
to the provirus would be an unlikely mechanism of transfor- 
mation (19, 21, 22). A number of studies have suggested that 
virus-encoded regulatory proteins may be involved in the trans- 
formation process. In addition to the typical gag, pol, and 
env  products  which  are  required  for  the  replication  of 
retroviruses, HTLV-I contains a region,  termed pX, which 
encodes at least two regulatory proteins, tax and rex (23, 24). 
Tax is a potent transcriptional transactivator of the provirus 
LTR (23, 24). In addition, tax can also transactivate and in- 
duce the expression of a number of heterologous cellular genes, 
some of which are known to be involved in T  cell growth, 
proliferation,  and possibly transformation  (19, 25). Cellular 
genes which  are known  to be transactivated  include IL-2, 
IL-2Rot, IL-3, IL-6, GM-CSF, and TNF-B (25-28). In addi- 
tion, tax can transactivate the parathyroid hormone-related 
protein  (PTHrP)  (29),  and the activity of this protein  ap- 
pears to be responsible for the hypercalcemia observed in acute 
ATL.  Tax  does not bind  to  the promoters  of these genes 
directly, but instead acts by binding to constitutively expressed 
cellular factors (25, 30). Although the mechanisms are un- 
known, it is believed that these interactions,  together with 
alterations in the host transcriptional  apparatus,  are impor- 
tant in cellular transformation.  Tax has also been shown to 
transactivate  the promoters of a number of oncogenes, in- 
cluding c-fos (31) and it is possible that  these may also be 
involved in cellular transformation. In addition, tax may down- 
regulate a number of important cellular genes. These include 
/3-polymerase, a DNA repair enzyme (32), and the absence 
of this activity may also be important  in transformation. 
The transactivation of IL-2 and IL-2R has led to a hypothet- 
ical model of HTLV-I-induced T cell transformation and the 
development of ATL (19, 28). Leukemogenesis is considered 
to be a multi-step process and HTLV-I infection is consid- 
ered to be the initial event. In the HTLV-I-infected cells, it 
is assumed that  tax transactivates the transcription  of both 
of these genes, and as a result the infected T  cells preferen- 
tially proliferate in response to autocrine  IL-2 production. 
It is believed that  the expansion of a cell population  with 
monoclonal provirus integration from the earlier stage where 
there is polyclonal integration requires a second genetic al- 
teration.  The molecular basis of this is unknown but could 
involve inactivation of a tumor suppressor gene or activation 
of an oncogene. This would represent the pre-leukemic state. 
Finally,  a single clone undergoes changes and expansion to 
complete the malignant transformation and the development 
of acute leukemia. 
Although the majority of patients with ATL are seroposi- 
tive for HTLV-I  and  the  leukemic cells  contain  an  intact 
provirus,  several  studies (33-36) have also shown that in a 
number of cases the provirus may contain deletions and may 
be defective. Importantly, many of these patients are seronega- 
tive (35), and it is assumed that the deletion(s) either elimi- 
nate or limit virus replication and this results in the seronega- 
rive state.  A striking and seemingly common feature of the 
deleted proviruses is that whereas the deletions appear to be 
random  and can vary in size and location in the provirus, 
the pX region generally remains unaffected (34-36). This high- 
lights  the importance of the pX encoded products,  and in 
particular,  the role of tax in cell proliferation and transfor- 
mation. 
The similarity of certain of the clinical and histopatholog- 
ical features of other CTCLs to ATL  has  led to a number 
of investigations to determine if HTLV-I or possibly a related 
retrovirus may also be associated with these disorders. These 
studies  have  focused primarily  on  the  CD30 +  anaplastic 
large cell CTCLs (LC-CTCLs), mycosis fungoides (MF), and 
its leukemic variant the Sezary Syndrome (SS). The anaplastic 
LC-CTCLs generally present as solitary or multiple tumors 
with the infiltrating  cells being large ceils with the CD4 § 
phenotype. The abnormal cells express high levels of activa- 
tion markers including CD30 and CD25 (37, 38), the latter 
also  being  characteristic  of the  CD4 +  T  lymphocytes in 
ATL. In a study of DNA from skin biopsies from five German 
patients  with  CD30 § LC-CTCLs,  Southern  hybridization 
and PCR analysis  demonstrated that  four and five, respec- 
tively, had evidence of HTLV-I infection (38). Importantly, 
the Southern hybridization analysis demonstrated that none 
of the four samples contained a full-length proviral DNA, 
suggesting that the proviruses may contain deletions and could 
possibly be defective. However, no attempts were made to 
directly demonstrate this by nucleotide sequence analysis, nor 
was it dear if the pX region was involved. Similarly,  serolog- 
ical studies were not carried out and it is known if these indi- 
viduals  may have  been  seronegative.  However the  studies 
do suggest  that  despite being in a nonendemic  area,  these 
CD30 + LC-CTCLs had an associated HTLV-I infection, and 
indicate a causal role for the virus. 
MF and  SS are also disorders  of CD4 + T  lymphocytes 
(39-42). These are generally of the small cell type and in con- 
trast to ATL and the CD30 + CTCLs, only infrequently ex- 
press activation markers such as CD25. MF has a similar clinical 
presentation  to smouldering  ATL in  that  this is usually a 
chronic  and  indolent  process.  The  characteristic  feature is 
infiltration of the skin by plaques and nodules composed of 
abnormal CD4 § T lymphocytes. The early stages of the dis- 
order  are characterized  by infiltration  of the cells  into the 
epidermis with intraepidermal  clusters of ceils forming the 
so-called Pautrier's microabscesses. With advancing disease, 
this epidermotropism  is progressively lost and is paralleled 
by infiltration of the cells to noncontiguous cutaneous sites 
and by hematogenous spread (39-42). Systemic involvement 
with a leukemia component is usually only a terminal event, 
and in contrast to ATL, bone marrow involvement generally 
does not occur. SS is considered to be a leukemic variant of 
MF and is characterized by erythroderma, lymphadenopathy, 
and atypical lymphocytes in peripheral blood. In contrast to 
MF, the infiltrating cells are primarily localized to the dermis 
with the epidermotropism observed in MF being much less 
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to that observed in various forms of ATL, and on occasion 
the two conditions may be di~cult  to differentiate.  It has 
been suggested that in SS the CD4 + T lymphocytes actively 
divide and proliferate in the dermis and their presence in pe- 
ripheral blood may be simply due to "overspill" (41).  The 
characteristic erythroderma is believed to be secondary to re- 
lease of vasoactive lymphokines by the infiltrating  lymphocytes. 
In view of the similarities of some of the features of MF 
and SS to ATL,  attempts  have been made to determine if 
HTLV-I may have a role in these disorders.  While two studies 
(43, 44) employing PCR to detect HTLV-I provirus in pa- 
tients from France and Portugal failed to demonstrate evi- 
dence of infection, a number of independent studies (45-49) 
on patients from Sweden, the United States, and the United 
Kingdom have shown that HTLV-I is certainly associated with 
at least some cases of these disorders. However, several of these 
investigations were limited by the small number of patients 
studied,  and  by  the  lack  of confirmation  of findings  in 
follow-up studies. In this volume of The Journal of  Experimental 
Medicine,  Manca et al.  (17) have addressed these issues  and 
have carried out a study on a cohort of 29 patients from Italy, 
a  nonendemic  area  for  HTLV-I  infection,  with  detailed 
documentation of their clinical  and pathological features. It 
could be shown that using PCR to amplify the regions of 
the HTLV-I pol and pX in DNA from cultured PBMC that 
10/29 (30%) had evidence of infection. Importantly, follow- 
up studies at 6 mo, under double-blind conditions, confirmed 
virus involvement in the same patients.  A  striking  feature 
of this study and in most of the previous studies is that the 
vast majority of patients with MF and SS who have HTLV-I 
involvement documented by molecular methods were found 
to be seronegative on routine screening.  As has been previ- 
ously discussed, a possible explanation is that the proviruses 
may contain  deletions and/or  are replication  defective. Al- 
though this has only been clearly documented by molecular 
methods in one patient  with MF (45),  it is supported in- 
directly in the studies of Manca et al. (17) by the observation 
that cultured lymphocytes did not produce the virus capsid 
p24 protein or reverse transcriptase activity. It is important 
to note that  the pX region was detected in all  10 patients, 
suggesting that  this region is also important  in the patho- 
genesis of these disorders. Further studies should determine 
if expression of the pX, and in particular tax, is as important 
in the proliferation  of infected lymphocytes in MF and SS 
as has been demonstrated for ATL. At present, it is unclear 
how many patients with MF and SS may have an associated 
HTLVoI  infection.  However,  this  would  appear  to  be  a 
minority;  whereas Manca et al.  (17)  have suggested this is 
30%, a previous study (48) and our own observations sug- 
gest that  this is in the range  of 10-15%. 
The observations that certain patients diagnosed with MF 
and SS have HTLV-I infection raise a number of questions 
as to how the disorders in these patients should be classified, 
and on the role of the virus in their pathogenesis.  The similarity 
of certain of the clinical and histopathological features of ATL 
to those in MF and SS raises the possibility that the diagnosis 
of the latter could in some cases be incorrect.  Moreover, it 
is presently unclear if the demonstration  of HTLV-I infec- 
tion in such a setting should automatically lead to a diag- 
nosis of ATL and not of MF or SS. In contrast, in those situ- 
ations  where  the  diagnosis  of MF  and  SS  can  be clearly 
established and differentiated from ATL, it will be very im- 
portant to determine if those with HTLV-I involvement may 
represent a unique subset of CTCLs. This will require a mul- 
tidisciplinary approach involving detailed clinical,  histolog- 
ical,  and immunological  studies and will require large pa- 
tient populations in both endemic and nonendemic areas. In 
addition, detailed molecular analysis will be required to de- 
termine if the proviruses contain deletions or are defective 
in those patients who are seronegative. Such studies will ul- 
timately better define the role of HTLV-I in the CTCLs and 
the mechanisms involved in T cell proliferation and transfor- 
mation. 
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